Opinion · 26 Dec 2024
Conference abstractPublished 2018
Tumor targeted pro-drugs
Mutah University, Egypt University of Bradford, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Matrix Metalloproteinases (MMPs) play a significant role in degrading the extra- cellular matrix in cancer development and metastasis. Overexpression of MMPs in tumor tissues relative to normal tissues has been exploited as a target for peptidebased therapeutics, to improve therapeutic index of currently used agents. The stability of MMP-activated pro-drugs in normal tissue or organs is a significant challenge for their success in the clinic. In an in vitro study, the stability of 26 pro-drugs was studied in mouse liver, kidney, lung and tumor homogenates using HPLC and LC/MS. Selected agents were studied in vivo. Each pro-drug has a characteristic amino acid sequence with dominant FITC N-terminal end cap. All pro-drugs were conjugated to a colchicine derivative (ICT 2552) which is a vascular disrupting agent causing tumor vasculature shutdown and consequently, tumor necrosis. ICT 3146, ICT 3019, ICT 3120 and ICT 3115 pro-drugs showed significant stability in normal tissues and considerable activation in certain tumor tissues compared to the lead compound ICT 2588. Also, the selectivity of promising pro-drugs to the MMP family was confirmed by using leupeptin (serine, cysteine and threonine protease inhibitor), pepstatin A (aspartate protease inhibitor), phosphoramidon (neprilysin inhibitor), ilomastat (metalloproteinase inhibitor) and BML-P115 (matrix metalloproteinase inhibitor). Moreover, members of the MMP family responsible for cleaving the selected pro-drugs were identified using recombinant MMP enzymes. Furthermore, a LC/MS-MS method was developed to specifically detect and quantify MMP-16 protein expression in H460 tumor. MMP-16 was responsible for the cleavage of ICT 3146 and ICT 3115. Therefore, MMP-activated pro-drugs could be a useful therapeutic approach to avoid off-site toxicities of currently used anti-tumor agents.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Forensic Toxicology & Pharmacology.
Commentary · 26 Dec 2024
Predictive Models for Toxicokinetics in Pharmaceuticals
Perspective · 26 Dec 2024
High-Performance Liquid Chromatography in Clinical Toxicology: Enhancing Diagnostic Precision
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Forensic Toxicology & Pharmacology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ahmed Youssef”
- BylineArticles whose byline prints “Paul Loadman”
- BylineArticles whose byline prints “Rob Falconer”

